SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Highlights Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-01-23			5-day change	1st Jan Change
10.59 ^CNY	+0.19%		-0.38%	+4.85%

Jan. 13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
Dec. 26	Shyndec Pharmaceutical Gets China Nod for Antipsychotic	MT

Highlights

Jan. 13	Shyndec Pharmaceutical's Generic Drug Secures Approval for Antibiotic Consistency Evaluation	MT
Dec. 12	Shyndec Pharma Gets Regulatory Approval for Cardiovascular Drug	MT
Dec. 01	Shanghai Shyndec Pharmaceutical Gets Registration for Opioid Analgesic	MT
Nov. 04	Shyndec Pharmaceutical Buys Rights for Lactulose Oral Solution	MT
25-10-29	Henan Yangsen Pharmaceutical Group Co., Ltd. completed the acquisition of an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd..	CI
25-10-29	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025	CI
25-10-17	Henan Yangsen Pharmaceutical Group Co., Ltd. agreed to acquire an additional 51% stake in Shanghai Modern Hasen Pharmaceutical Co., Ltd. from Shanghai Shyndec Pharmaceutical Co., Ltd. for approximately CNY 110 million.	CI
25-09-01	Shyndec Pharma Obtains Drug Registration for Chest Pain Drug	MT
25-08-29	Shanghai Shyndec Pharmaceutical H1 net profit down 6.5% Y/Y	RE
25-07-18	Shyndec Pharmaceutical's H1 Profit Slips 7%, Total Revenue Drops 18%	MT
25-07-17	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-07-17	Shanghai Shyndec Pharmaceutical prelim H1 net profit down 6.5% Y/Y	RE
25-06-05	Shyndec Pharmaceutical's Two Drugs Pass Regulatory Evaluation	MT
25-05-14	Shyndec Pharmaceutical Unit's Amikacin Sulfate Injection Passes Regulatory Consistency Evaluation	MT
25-04-28	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
25-04-16	Shyndec Pharmaceutical Passes Consistency Evaluation for Antibiotic Drug	MT
25-03-27	Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-03-18	Shyndec Pharmaceutical Subsidiary Passes Generic Drug Consistency Evaluation for Asthma Drug	MT
25-03-17	Shyndec Pharmaceutical's Unit Gets Registration Certificate for Methylprednisolone Tablets	MT
25-03-10	Shyndec Pharmaceutical Obtains Registration Certificates for Antiviral, Anticoagulant Drugs	MT
25-03-03	Shanghai Shyndec Pharmaceutical's Pravastatin Sodium Tablets Passes Chinese Drug Regulator's Consistency Evaluation	MT
25-01-22	Shyndec Pharma's Units Get Three Drug Registration Certificates	MT
25-01-20	Shanghai Shyndec's Shenzhen Unit Passes EU GMP Inspection	MT
25-01-20	Shyndec Pharma Unit's Cefuroxime Sodium for Injection Passes Regulatory Consistency Evaluation	MT
25-01-03	Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Highlights Shanghai Shyndec Pharmaceutical Co., Ltd.

Equities

600420

CNE000001JG2

Pharmaceuticals

Highlights

Filters